About ILCN

IASLC Lung Cancer News is published bimonthly by the International Association for the Study of Lung Cancer (IASLC). For more information email Erin Jungmeyer at [email protected].

ILCN Editorial Group

Editor
Corey J. Langer, MD, FACP

Associate Editors 
Mary Jo Fidler, MD 
Witold K. Rzyman, MD
Suresh Senan, MD 

Editorial Group Members 

Fabrice Barlesi, MD, PhD	Angus Pratt, MBA
Ross Camidge, MD, PhD	Karen Reckamp, MD
Edgardo S. Santos Castillero, MD, FACP	Christian Rolfo, MD, PhD, MBA
Jose Francisco Corona Cruz, MD, FACP	Ricardo Sales dos Santos, MD, PhD
Marianne Davies, DNP, ACNP, AOCNP	Joan H. Schiller, MD, FACP
Anne-Marie C. Dingemans, MD, PhD	Brendon Stiles, MD
Terri Ann DiJulio	Aaron Tan, MD, PhD, FRACP
Shirish Gadgeel, MDG	Ricardo Terra, MD, PhD, MPH
Bruno Hochhegger, MD, PhD	Murry Wynes, PhD
Deepali Jain, MD	Caicun Zhou, MD, PhD

Publisher 
TriStar Event Media

Managing Editor
Erin Jungmeyer, Special Projects Editor
TriStar Event Media
[email protected]

Advertising Sales
Nan Blunk, Senior Media Strategist
[email protected]

IASLC Staff Liaison 
Jan Mazotti, Associate Director of Communications & Marketing
International Association for the Study of Lung Cancer

Submission Guidelines

ILCN accepts manuscripts from authors with experience in the field of lung cancer and other thoracic malignancies, including physicians, researchers, patients and patient advocates, and allied health professionals. Authors interested in publishing in ILCN should send manuscripts to Erin Jungmeyer at [email protected]. See guidelines below for more information.  

General Guidance

• ILCN is not a formal journal, so articles can be more conversational. They do not need to follow a scientific journal article format. However, articles should be clearly organized, and statements of facts and any data or evidence shared should be cited in a reference section at the end of the article.
• Co-authors are welcome, though we suggest no more than three to five authors per submission. All listed authors should submit a photo and provide a brief bio, including credentials and affiliations.
• Graphics such as charts, tables, or images that may aid readers in understanding articles are strongly encouraged. When submitting artwork with an article, please let us know if the image has been previously published, and if so, if reprint permission will be needed.

Submissions Accepted

• Analysis & Contextualization: ILCN publishes articles that analyze recent thoracic oncology research and those that put such research into context for clinicians. Investigators who have recently published research related to thoracic oncology are invited to put that research into context in an article for ILCN. Additionally, authors are invited to offer broader analysis of recent developments or challenges in lung cancer management or research. This could range from summaries of pertinent research for a given genetic mutation to a comparison of the efficacy of smoking cessation programs around the globe. Analytical articles should range from about 750 words to 1,500 words. If the topic cannot be adequately covered in 1,500 words (excluding references), consider submitting the article in two or more parts.

• Editorials: ILCN accepts opinion articles related to thoracic oncology. While presenting an opinion, editorial writing should still be grounded in science, and opinions should be supported by studies or data where appropriated. Editorial submissions should strive for about 750 words (excluding references). If the subject cannot be adequately covered in roughly 750 words, consider submitting your comment in two or more parts as a series.  
• Pro/Con Debates: Two or more authors may work together to provide differing analysis or opinion of a topic for an ILCN article. Like other submissions, any evidence or data presented as part of the argument should be cited and included in the references at the end. Pro/Con articles can be submitted as one article of 1,000-2,000 words or as a 2-part series. If submitted as a series, each submission should aim for roughly 750-1,000 words.
• Patient Perspectives: ILCN welcomes insights from patients and patient advocates. Articles from the patient perspective should range from 500 to 1,000 words. If a story cannot be told in about 1,000 words or less, consider submitting the article in two or more parts. 
• Historical Perspectives: Authors with insights into the evolution of research, treatments, screening, or other aspects of thoracic oncology are welcome to submit articles sharing those insights and putting the lessons that might be learned from the past into context for today’s lung cancer community. Authors of historical perspective articles should aim for 750-1,500 words.
• News & Announcements: ILCN accepts announcements and press releases of lung cancer related news. Examples include new appointments or job changes, funding opportunities, information on upcoming meetings, etc.
• Letters to the Editor: Have a question or comment for our editorial group? Either on something you’ve seen in ILCN or elsewhere? Send an email to [email protected]. Comments should be no more than 250-300 words. Please include your contact information as well as your name and any credentials and affiliations.